董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Gregory Behar | 男 | Director | 47 | 64.14万美元 | 未持股 | 2017-03-31 |
| Mark T. Iwicki | 男 | Director | 50 | 23.71万美元 | 未持股 | 2017-03-31 |
| Stacey D. Seltzer | 女 | Director | 40 | 24.11万美元 | 未持股 | 2017-03-31 |
| Mark D. McDade | 男 | Chair of the Board | 62 | 27.11万美元 | 未持股 | 2017-03-31 |
| Patrick G. Enright | 男 | Director | 55 | 24.31万美元 | 未持股 | 2017-03-31 |
| Kathryn E. Falberg | 女 | Director | 56 | 25.31万美元 | 未持股 | 2017-03-31 |
| Stephen G. Dilly | 男 | President, Chief Executive Officer and Director | 57 | 333.58万美元 | 未持股 | 2017-03-31 |
| Mark D. McDade | 男 | Chair of the Board | 61 | 未披露 | 未持股 | 2017-03-31 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Warren L. DeSouza | 男 | Chief Financial Officer | 48 | 171.25万美元 | 未持股 | 2017-03-31 |
| Mary M. Rozenman | 女 | Senior Vice President, Strategy & Corporate Development | 36 | 106.19万美元 | 未持股 | 2017-03-31 |
| Susan E. Barrowcliffe | 女 | Senior Vice President, General Manager of Europe | 59 | 未披露 | 未持股 | 2017-03-31 |
| Daniel C. Adelman | 男 | Chief Medical Officer | 59 | 217.41万美元 | 未持股 | 2017-03-31 |
| Jeffrey H. Knapp | 男 | Chief Operating Officer | 51 | 350.97万美元 | 未持股 | 2017-03-31 |
| Stephen G. Dilly | 男 | President, Chief Executive Officer and Director | 57 | 333.58万美元 | 未持股 | 2017-03-31 |
| Douglas T. Sheehy | 男 | General Counsel and Secretary | 50 | 未披露 | 未持股 | 2017-03-31 |
董事简历
中英对照 | 中文 | 英文- Gregory Behar
-
Gregory Behar，2014年12月起担任本公司董事会成员。2014年10月起在一家健康科学公司- Nestlé Health Science S.A.担任首席执行官。2011年7月-2014年7月，在一家医药公司- Boehringer Ingelheim Pharmaceuticals Inc. USA担任总裁和首席执行官。2010年-2011年7月，在一家医药公司- Boehringer-Ingelheim GmbH（欧盟北部、加拿大和澳大拉西亚）担任企业区域副总裁。他持有洛杉矶市California大学的学士学位、瑞士EPFL的机械工程和制造硕士学位，以及法国INSEAD的工商管理硕士学位。
Gregory Behar has served as a member of our Board of Directors since December 2014. Mr. Behar has served as Chief Executive Officer of Nestlé Health Science, a business unit of Société des Produits Nestlé S.A., a health sciences company, since July 2014. From July 2011 to July 2014 Mr. Behar was President and Chief Executive Officer of Boehringer Ingelheim Pharmaceuticals Inc. USA, a pharmaceutical company. From 2010 to July 2011 Mr. Behar was Corporate Vice President Region NECAR (North European Union, Canada and Australasia) for Boehringer-Ingelheim GmbH, a pharmaceutical company. Mr. Behar has served on the board of directors of Axcella Health, Inc. since February 2016 and previously served on the board of directors of Aimmune Therapeutics, Inc. from November 2016 until its acquisition in October 2020. Mr. Behar also serves on the boards of directors of numerous privately held companies. Mr. Behar received his B.S. in Mechanical Engineering from the University of California, Los Angeles, an M.S. in Mechanical Engineering and Manufacturing from EPFL in Switzerland and an M.B.A. from INSEAD in France. - Gregory Behar，2014年12月起担任本公司董事会成员。2014年10月起在一家健康科学公司- Nestlé Health Science S.A.担任首席执行官。2011年7月-2014年7月，在一家医药公司- Boehringer Ingelheim Pharmaceuticals Inc. USA担任总裁和首席执行官。2010年-2011年7月，在一家医药公司- Boehringer-Ingelheim GmbH（欧盟北部、加拿大和澳大拉西亚）担任企业区域副总裁。他持有洛杉矶市California大学的学士学位、瑞士EPFL的机械工程和制造硕士学位，以及法国INSEAD的工商管理硕士学位。
- Gregory Behar has served as a member of our Board of Directors since December 2014. Mr. Behar has served as Chief Executive Officer of Nestlé Health Science, a business unit of Société des Produits Nestlé S.A., a health sciences company, since July 2014. From July 2011 to July 2014 Mr. Behar was President and Chief Executive Officer of Boehringer Ingelheim Pharmaceuticals Inc. USA, a pharmaceutical company. From 2010 to July 2011 Mr. Behar was Corporate Vice President Region NECAR (North European Union, Canada and Australasia) for Boehringer-Ingelheim GmbH, a pharmaceutical company. Mr. Behar has served on the board of directors of Axcella Health, Inc. since February 2016 and previously served on the board of directors of Aimmune Therapeutics, Inc. from November 2016 until its acquisition in October 2020. Mr. Behar also serves on the boards of directors of numerous privately held companies. Mr. Behar received his B.S. in Mechanical Engineering from the University of California, Los Angeles, an M.S. in Mechanical Engineering and Manufacturing from EPFL in Switzerland and an M.B.A. from INSEAD in France.
- Mark T. Iwicki
-
Mark T. Iwicki，2015年5月以来，他一直担任我们的董事会成员。他曾担任Civitas Therapeutics公司（生物制药公司）的总裁兼首席执行官，以及董事会成员（始于2014年1月），直到2014年9月公司被Acorda Therapeutics公司（生物制药公司）收购。从2012年12月到2014年1月，他担任Blend Therapeutics公司（一个生物制药公司）的总裁兼首席执行官、董事。从2007年到2012年6月，他曾担任Sunovion Pharmaceuticals公司（原为Sepracor公司，一家制药公司）的总裁兼首席执行官、董事。从1998年到2007年，他曾担任Novartis Pharmaceuticals Corporation（制药公司）副总裁兼商业单位主管。他也曾担任Astra Merck公司、Merck公司（制药公司）的管理职务。他拥有Ball State University的工商管理学士学位，以及Loyola University的工商管理硕士学位。
Mark T. Iwicki has served as a member of our Board since May 2015. Mr. Iwicki currently serves as the Chairman and Chief Executive Officer of Kala Pharmaceuticals, Inc., a biopharmaceutical company, which he joined in April 2015. Mr. Iwicki also currently serves as the Chairman of the board of directors and a member of the compensation committee of Pulmatrix, Inc., a biopharmaceutical company, Chairman of the board of directors and member of the compensation committee of Merus B.V., a biopharmaceutical company, and a member of the board of directors of each of Nimbus Therapeutics LLC and Taris Biomedical, LLC, biotechnology companies. Previously, Mr. Iwicki served as President and Chief Executive Officer and a member of the board of directors of Civitas Therapeutics, Inc., a biopharmaceutical company, from January 2014 until its acquisition by Acorda Therapeutics, Inc., a biotechnology company, in September 2014. From December 2012 to January 2014 Mr. Iwicki served as President and Chief Executive Officer and director at Blend Therapeutics, Inc., a biopharmaceutical company. From 2007 to June 2012 Mr. Iwicki served in several roles, including Chief Commercial Officer, President and Chief Operating Officer and Director and Chief Executive Officer at Sunovion Pharmaceuticals, Inc., formerly Sepracor, Inc., a pharmaceutical company. From 1998 to 2007 Mr. Iwicki held executive positions, including Vice President and Business Unit Head, at Novartis Pharmaceuticals Corporation, a pharmaceuticals company. Mr. Iwicki has also held management positions at Astra Merck Inc. and Merck & Co., Inc., pharmaceutical companies. Mr. Iwicki received a B.A. in Business Administration from Ball State University and an M.B.A. from Loyola University. - Mark T. Iwicki，2015年5月以来，他一直担任我们的董事会成员。他曾担任Civitas Therapeutics公司（生物制药公司）的总裁兼首席执行官，以及董事会成员（始于2014年1月），直到2014年9月公司被Acorda Therapeutics公司（生物制药公司）收购。从2012年12月到2014年1月，他担任Blend Therapeutics公司（一个生物制药公司）的总裁兼首席执行官、董事。从2007年到2012年6月，他曾担任Sunovion Pharmaceuticals公司（原为Sepracor公司，一家制药公司）的总裁兼首席执行官、董事。从1998年到2007年，他曾担任Novartis Pharmaceuticals Corporation（制药公司）副总裁兼商业单位主管。他也曾担任Astra Merck公司、Merck公司（制药公司）的管理职务。他拥有Ball State University的工商管理学士学位，以及Loyola University的工商管理硕士学位。
- Mark T. Iwicki has served as a member of our Board since May 2015. Mr. Iwicki currently serves as the Chairman and Chief Executive Officer of Kala Pharmaceuticals, Inc., a biopharmaceutical company, which he joined in April 2015. Mr. Iwicki also currently serves as the Chairman of the board of directors and a member of the compensation committee of Pulmatrix, Inc., a biopharmaceutical company, Chairman of the board of directors and member of the compensation committee of Merus B.V., a biopharmaceutical company, and a member of the board of directors of each of Nimbus Therapeutics LLC and Taris Biomedical, LLC, biotechnology companies. Previously, Mr. Iwicki served as President and Chief Executive Officer and a member of the board of directors of Civitas Therapeutics, Inc., a biopharmaceutical company, from January 2014 until its acquisition by Acorda Therapeutics, Inc., a biotechnology company, in September 2014. From December 2012 to January 2014 Mr. Iwicki served as President and Chief Executive Officer and director at Blend Therapeutics, Inc., a biopharmaceutical company. From 2007 to June 2012 Mr. Iwicki served in several roles, including Chief Commercial Officer, President and Chief Operating Officer and Director and Chief Executive Officer at Sunovion Pharmaceuticals, Inc., formerly Sepracor, Inc., a pharmaceutical company. From 1998 to 2007 Mr. Iwicki held executive positions, including Vice President and Business Unit Head, at Novartis Pharmaceuticals Corporation, a pharmaceuticals company. Mr. Iwicki has also held management positions at Astra Merck Inc. and Merck & Co., Inc., pharmaceutical companies. Mr. Iwicki received a B.A. in Business Administration from Ball State University and an M.B.A. from Loyola University.
- Stacey D. Seltzer
-
Stacey D. Seltzer，她担任我们的董事会成员（2015年1月以来）。她是Aisling Capital公司的现任合伙人，在那里她此前曾担任负责人（2008年9月加入公司以来）。从2004年到2008年，她曾担任Schering-Plough Corporation（制药公司）的多种职务，包括美国Schering-Plough的Zetia品牌领导人、美国营销副董事、高级全球授权经理、管理合伙人。从2001年到2002年，她曾担任Akceli公司（一个生物技术公司）的业务拓展董事。她也任职于Miramar Labs公司（一家民营医疗设备公司）的董事会。她此前曾担任Agile Therapeutics公司（一家制药公司）、Durata Therapeutics公司（一家制药公司）、Zeltiq Aesthetics公司（医疗设备供应商）的董事会监察员。她持有Yale University的分子生物物理学和生物化学学士和硕士学位，以及宾夕法尼亚大学沃顿商学院（the Wharton School at the University of Pennsylvania）的工商管理硕士学位。
Stacey D. Seltzer has served as a member of our board of directors since December 2020. Since 2014 Ms. Seltzer has served as a partner at Aisling Capital LLC, a venture capital and private equity firm, where she previously served as principal from 2008 to 2014. From 2004 to 2008 Ms. Seltzer held various positions at Schering-Plough Corporation, a pharmaceutical company, including U.S. Schering-Plough Brand Lead for Zetia, Associate Director, U.S. Marketing, Senior Manager, Global Licensing and Management Associate. From 2001 to 2002 Ms. Seltzer served as Director of Business Development for Akceli, Inc., a biotechnology company. Ms. Seltzer has served on the board of directors of Promentis Pharmaceuticals, Inc., a private biopharmaceutical company, since November 2016 and is currently a board observer for Prolacta Bioscience Inc., a private biopharmaceutical company. Ms. Seltzer previously served on the board of directors of Miramar Labs, Inc., a public global medical device company, from May 2013 to July 2017 Aimmune Therapeutics, Inc., a public biopharmaceutical company, from January 2015 to October 2020 and as a board observer for public companies, Agile Therapeutics, Inc., a women’s healthcare company and Durata Therapeutics, Inc., a pharmaceutical company. Ms. Seltzer received a B.S. and M.S. in Molecular Biophysics and Biochemistry from Yale University and an M.B.A. from the Wharton School at the University of Pennsylvania. - Stacey D. Seltzer，她担任我们的董事会成员（2015年1月以来）。她是Aisling Capital公司的现任合伙人，在那里她此前曾担任负责人（2008年9月加入公司以来）。从2004年到2008年，她曾担任Schering-Plough Corporation（制药公司）的多种职务，包括美国Schering-Plough的Zetia品牌领导人、美国营销副董事、高级全球授权经理、管理合伙人。从2001年到2002年，她曾担任Akceli公司（一个生物技术公司）的业务拓展董事。她也任职于Miramar Labs公司（一家民营医疗设备公司）的董事会。她此前曾担任Agile Therapeutics公司（一家制药公司）、Durata Therapeutics公司（一家制药公司）、Zeltiq Aesthetics公司（医疗设备供应商）的董事会监察员。她持有Yale University的分子生物物理学和生物化学学士和硕士学位，以及宾夕法尼亚大学沃顿商学院（the Wharton School at the University of Pennsylvania）的工商管理硕士学位。
- Stacey D. Seltzer has served as a member of our board of directors since December 2020. Since 2014 Ms. Seltzer has served as a partner at Aisling Capital LLC, a venture capital and private equity firm, where she previously served as principal from 2008 to 2014. From 2004 to 2008 Ms. Seltzer held various positions at Schering-Plough Corporation, a pharmaceutical company, including U.S. Schering-Plough Brand Lead for Zetia, Associate Director, U.S. Marketing, Senior Manager, Global Licensing and Management Associate. From 2001 to 2002 Ms. Seltzer served as Director of Business Development for Akceli, Inc., a biotechnology company. Ms. Seltzer has served on the board of directors of Promentis Pharmaceuticals, Inc., a private biopharmaceutical company, since November 2016 and is currently a board observer for Prolacta Bioscience Inc., a private biopharmaceutical company. Ms. Seltzer previously served on the board of directors of Miramar Labs, Inc., a public global medical device company, from May 2013 to July 2017 Aimmune Therapeutics, Inc., a public biopharmaceutical company, from January 2015 to October 2020 and as a board observer for public companies, Agile Therapeutics, Inc., a women’s healthcare company and Durata Therapeutics, Inc., a pharmaceutical company. Ms. Seltzer received a B.S. and M.S. in Molecular Biophysics and Biochemistry from Yale University and an M.B.A. from the Wharton School at the University of Pennsylvania.
- Mark D. McDade
-
Mark D. McDade自2019年8月起担任Icosavax, Inc.的董事。自2017年1月起，他担任启明美国医疗保健基金（一家风险投资公司）的管理合伙人。他曾担任UCB s.a.（比利时生物制药公司）的执行副总裁兼首席运营官（从2009年到2016年10月退休），2008年以来担任企业发展执行副总裁。从2002年到2007年，他担任PDL BioPharma, Inc.（生物技术公司）的首席执行官和董事会成员。从2000年到2002年，他担任Signature BioScience, Inc.（药物发现公司）的首席执行官。从1994年到2000年，他担任Corixa Corporation（他共同创立的生物制药公司）的首席运营官和董事。从1998年到2000年，他还担任Corixa的总裁。自2021年2月起，他担任上市跨国制药公司卢平有限公司（Lupin Ltd.）的董事会成员。他曾在Dermira董事会，Inc 。生物制药公司从2014年8月，直到2020年2月收购了礼来和担任董事会主席Aimmune疗法从2014年5月到2020年10月由雀巢公司收购。从2006年到2018年11月，他还担任Five Prime Therapeutics, Inc.（生物技术公司）的董事会成员。麦克达德先生担任董事会的成员，成员的审计和委员会Phillips Edison Grocery Center REIT II，非贸易房地产投资公司，直到2018年11月，担任独立董事在Phillips Edison Grocery Center REIT III，从2018年11月到2019年11月被Phillips Edison & Company, Inc.收购。此外，他是几家私人控股公司的董事会成员。他持有Dartmouth College的历史学学士学位和哈佛商学院（Harvard Business School）的工商管理硕士学位。
Mark D. McDade,has been co-founder and Managing Partner of the Qiming US Healthcare Fund, a venture capital firm based in Seattle and formed in January 2017. Prior to Qiming, from April 2008, Mr. McDade was Executive Vice President, Corporate Development, and from January 2009, EVP and Chief Operating Officer, at UCB S.A. (OTC: UCBJF), a Belgian biopharmaceutical company, until his retirement from UCB in October 2016. From November 2002 to September 2007, Mr. McDade served as Chief Executive Officer and a member of the board of directors of PDL BioPharma, Inc. (Nasdaq: PDLI), a biotechnology company. From 2000 to 2002, Mr. McDade was Chief Executive Officer of Signature BioScience, Inc., a drug discovery company. Previously, Mr. McDade also served on the board of directors of Dermira, Inc. (Nasdaq: DERM), and as chairman of the board of Aimmune Therapeutics, Inc. (Nasdaq: AIMT), until both companies were acquired by Eli Lilly and Company (NYSE: LLY) and Nestle SA (OTC: NSRGY), respectively, in March and October 2020. Previously, Mr. McDade also served on the board of directors of publicly traded companies Phillips Edison Grocery Center REIT II, Inc. and Five Prime Therapeutics, Inc. (Nasdaq: FPRX). Mr. McDade received a B.A. in History from Dartmouth College and an M.B.A. from the Harvard Business School. - Mark D. McDade自2019年8月起担任Icosavax, Inc.的董事。自2017年1月起，他担任启明美国医疗保健基金（一家风险投资公司）的管理合伙人。他曾担任UCB s.a.（比利时生物制药公司）的执行副总裁兼首席运营官（从2009年到2016年10月退休），2008年以来担任企业发展执行副总裁。从2002年到2007年，他担任PDL BioPharma, Inc.（生物技术公司）的首席执行官和董事会成员。从2000年到2002年，他担任Signature BioScience, Inc.（药物发现公司）的首席执行官。从1994年到2000年，他担任Corixa Corporation（他共同创立的生物制药公司）的首席运营官和董事。从1998年到2000年，他还担任Corixa的总裁。自2021年2月起，他担任上市跨国制药公司卢平有限公司（Lupin Ltd.）的董事会成员。他曾在Dermira董事会，Inc 。生物制药公司从2014年8月，直到2020年2月收购了礼来和担任董事会主席Aimmune疗法从2014年5月到2020年10月由雀巢公司收购。从2006年到2018年11月，他还担任Five Prime Therapeutics, Inc.（生物技术公司）的董事会成员。麦克达德先生担任董事会的成员，成员的审计和委员会Phillips Edison Grocery Center REIT II，非贸易房地产投资公司，直到2018年11月，担任独立董事在Phillips Edison Grocery Center REIT III，从2018年11月到2019年11月被Phillips Edison & Company, Inc.收购。此外，他是几家私人控股公司的董事会成员。他持有Dartmouth College的历史学学士学位和哈佛商学院（Harvard Business School）的工商管理硕士学位。
- Mark D. McDade,has been co-founder and Managing Partner of the Qiming US Healthcare Fund, a venture capital firm based in Seattle and formed in January 2017. Prior to Qiming, from April 2008, Mr. McDade was Executive Vice President, Corporate Development, and from January 2009, EVP and Chief Operating Officer, at UCB S.A. (OTC: UCBJF), a Belgian biopharmaceutical company, until his retirement from UCB in October 2016. From November 2002 to September 2007, Mr. McDade served as Chief Executive Officer and a member of the board of directors of PDL BioPharma, Inc. (Nasdaq: PDLI), a biotechnology company. From 2000 to 2002, Mr. McDade was Chief Executive Officer of Signature BioScience, Inc., a drug discovery company. Previously, Mr. McDade also served on the board of directors of Dermira, Inc. (Nasdaq: DERM), and as chairman of the board of Aimmune Therapeutics, Inc. (Nasdaq: AIMT), until both companies were acquired by Eli Lilly and Company (NYSE: LLY) and Nestle SA (OTC: NSRGY), respectively, in March and October 2020. Previously, Mr. McDade also served on the board of directors of publicly traded companies Phillips Edison Grocery Center REIT II, Inc. and Five Prime Therapeutics, Inc. (Nasdaq: FPRX). Mr. McDade received a B.A. in History from Dartmouth College and an M.B.A. from the Harvard Business School.
- Patrick G. Enright
-
Patrick G. Enright，与Azur合并之时起，担任Jazz Pharmaceuticals董事；2009年直到与Azur合并，担任Jazz Pharmaceuticals的董事。2006年以来，他一直担任风投公司Longitude Capital的董事总经理，他是该公司的创始人。2002-2006，他担任风投公司Pequot Ventures的董事总经理，共同领导生命科学行业的投资业务。他目前是2家制药公司Corcept Therapeutics Incorporated、Esperion Therapeutics，以及一些私营公司的董事。过去的5年里，他还曾担任Threshold Pharmaceuticals、Sequenom的董事。他在Stanford大学获得学士学位，在Wharton School at the Pennsylvania大学获得工商管理硕士学位。
Patrick G. Enright,has served as a member of Jazz Pharmaceuticals Public Limited Company board of directors since the closing of the Azur Merger in January 2012 and was a director of Jazz Pharmaceuticals, Inc. from 2009 until the closing of the Azur Merger. Mr. Enright co-founded Longitude Capital, a healthcare venture capital firm, where he has served as a Managing Director since 2006. Mr. Enright currently serves on the board of directors of Vera Therapeutics, Inc. and privately held healthcare companies as well as the National Venture Capital Association. Previously, Mr. Enright was a Managing Director of Pequot Ventures where he co-led the life sciences investment practice. Mr. Enright also has significant life sciences operations experience including holding senior executive positions at Valentis, Boehringer Mannheim (acquired by Roche) and Sandoz (now known as Novartis). Mr. Enright previously served on the boards of directors of over twenty companies, including Aptinyx Inc. from 2016 to 2022, Aimmune Therapeutics, Inc. from 2013 until its acquisition by Nestlé in 2020 and Vaxcyte, Inc. from 2015 to 2020. Mr. Enright received a B.S. in Biological Sciences from Stanford University and an M.B.A. from the Wharton School of the University of Pennsylvania. - Patrick G. Enright，与Azur合并之时起，担任Jazz Pharmaceuticals董事；2009年直到与Azur合并，担任Jazz Pharmaceuticals的董事。2006年以来，他一直担任风投公司Longitude Capital的董事总经理，他是该公司的创始人。2002-2006，他担任风投公司Pequot Ventures的董事总经理，共同领导生命科学行业的投资业务。他目前是2家制药公司Corcept Therapeutics Incorporated、Esperion Therapeutics，以及一些私营公司的董事。过去的5年里，他还曾担任Threshold Pharmaceuticals、Sequenom的董事。他在Stanford大学获得学士学位，在Wharton School at the Pennsylvania大学获得工商管理硕士学位。
- Patrick G. Enright,has served as a member of Jazz Pharmaceuticals Public Limited Company board of directors since the closing of the Azur Merger in January 2012 and was a director of Jazz Pharmaceuticals, Inc. from 2009 until the closing of the Azur Merger. Mr. Enright co-founded Longitude Capital, a healthcare venture capital firm, where he has served as a Managing Director since 2006. Mr. Enright currently serves on the board of directors of Vera Therapeutics, Inc. and privately held healthcare companies as well as the National Venture Capital Association. Previously, Mr. Enright was a Managing Director of Pequot Ventures where he co-led the life sciences investment practice. Mr. Enright also has significant life sciences operations experience including holding senior executive positions at Valentis, Boehringer Mannheim (acquired by Roche) and Sandoz (now known as Novartis). Mr. Enright previously served on the boards of directors of over twenty companies, including Aptinyx Inc. from 2016 to 2022, Aimmune Therapeutics, Inc. from 2013 until its acquisition by Nestlé in 2020 and Vaxcyte, Inc. from 2015 to 2020. Mr. Enright received a B.S. in Biological Sciences from Stanford University and an M.B.A. from the Wharton School of the University of Pennsylvania.
- Kathryn E. Falberg
-
Kathryn E. Falberg，她贡献着相当大的关于医疗保健行业，尤其是在财务、会计、战略、业务及运营方面的知识。2012年3月至2014年3月，她担任Jazz Pharmaceuticals, PLC（纳斯达克代码： JAZZ）的执行副总裁、首席财务官；此前，她从2009年12月起，担任其高级副总裁、首席财务官。2001-2009，她曾在一些小公司工作，并在一些公司担任公司董事和审核委员会主席。1995-2001，她担任Amgen的财务与战略高级副总裁、首席财务官；此前，她曾担任副总裁、财务总监、首席会计官、副总裁、财务总管。她获得了University of California, Los Angeles的工商管理硕士学位、经济学学士学位，是一名注册会计师。她现在任Medivation, Inc. （纳斯达克代码： MDVN）的董事会成员、审核委员会主席。
Kathryn E. Falberg,has served as a member of The Trade Desk, Inc. board of directors since August 2016. Ms. Falberg served as executive vice president and chief financial officer of Jazz Pharmaceuticals, PLC, a biopharmaceutical company, from March 2012 to March 2014 after serving as senior vice president and chief financial officer since December 2009. From 2001 through 2009, Ms. Falberg worked with a number of smaller companies, including AdECN, Inc. ("AdECN"), while serving as a corporate director and audit committee chair for several companies. Ms. Falberg was with Amgen from 1995 through 2001, where she served as senior vice president, finance and strategy and chief financial officer and before that as vice president, controller and chief accounting officer, and vice president, treasurer. Ms. Falberg currently serves on the board of directors of publicly traded Arcus Biosciences, Inc., Nuvation Bio and Tricida, Inc., and previously served on a number of boards including publicly traded Urogen Pharma Ltd., Aimmune Therapeutics, Inc., Axovant Sciences Ltd., BioMarin Pharmaceutical Inc, Medivation, Inc., Halozyme Therapeutics, Inc., and aTyr Pharma, Inc. Ms. Falberg received a B.A. in Economics and an M.B.A. from the University of California, Los Angeles and is a Certified Public Accountant (inactive). - Kathryn E. Falberg，她贡献着相当大的关于医疗保健行业，尤其是在财务、会计、战略、业务及运营方面的知识。2012年3月至2014年3月，她担任Jazz Pharmaceuticals, PLC（纳斯达克代码： JAZZ）的执行副总裁、首席财务官；此前，她从2009年12月起，担任其高级副总裁、首席财务官。2001-2009，她曾在一些小公司工作，并在一些公司担任公司董事和审核委员会主席。1995-2001，她担任Amgen的财务与战略高级副总裁、首席财务官；此前，她曾担任副总裁、财务总监、首席会计官、副总裁、财务总管。她获得了University of California, Los Angeles的工商管理硕士学位、经济学学士学位，是一名注册会计师。她现在任Medivation, Inc. （纳斯达克代码： MDVN）的董事会成员、审核委员会主席。
- Kathryn E. Falberg,has served as a member of The Trade Desk, Inc. board of directors since August 2016. Ms. Falberg served as executive vice president and chief financial officer of Jazz Pharmaceuticals, PLC, a biopharmaceutical company, from March 2012 to March 2014 after serving as senior vice president and chief financial officer since December 2009. From 2001 through 2009, Ms. Falberg worked with a number of smaller companies, including AdECN, Inc. ("AdECN"), while serving as a corporate director and audit committee chair for several companies. Ms. Falberg was with Amgen from 1995 through 2001, where she served as senior vice president, finance and strategy and chief financial officer and before that as vice president, controller and chief accounting officer, and vice president, treasurer. Ms. Falberg currently serves on the board of directors of publicly traded Arcus Biosciences, Inc., Nuvation Bio and Tricida, Inc., and previously served on a number of boards including publicly traded Urogen Pharma Ltd., Aimmune Therapeutics, Inc., Axovant Sciences Ltd., BioMarin Pharmaceutical Inc, Medivation, Inc., Halozyme Therapeutics, Inc., and aTyr Pharma, Inc. Ms. Falberg received a B.A. in Economics and an M.B.A. from the University of California, Los Angeles and is a Certified Public Accountant (inactive).
- Stephen G. Dilly
-
Stephen G. Dilly，2010年3月起担任公司董事会成员。2012年1月孩子12月，他担任医疗设备公司PhotoThera, Inc.的首席执行官。2006至2011年12月，他担任药物研发公司APT Pharmaceuticals, Inc.的总裁、首席执行官、董事会成员。2007至2009年，他担任生物制药公司Avigen, Inc.的董事会成员，该公司2009年12月与MediciNova, Inc.合并。2003至2006年，他担任生物科技公司Chiron BioPharma的首席医务官和发展部高级副总裁，该公司后被Novartis International AG收购。1998至2003年，他在Genentech, Inc.担任多个职位，包括2002至2003年任发展科学副总裁，1998至2001担任医疗事务副总裁。1988至1998年，他在英国SmithKline Beecham担任药物开发多个管理职位。在此期间，他密切协助诸多治疗领域的市场化药品的开发和推广，包括Kytril, Paxil, Kredex, Requip, TNKase, Xolair, Avastin, Raptiva, Tarceva, Lucentis以及Cubicin。他现任Allergen Research Corporation Inc.的执行主席。1982年，他获得英国University of London的硕士学位，1988年获得University of London心脏生理学博士学位。
Stephen G. Dilly, M.B.B.S., Ph.D. has served as our Chief Executive Officer since April 2014 and as a member of our Board since April 2013. Dr. Dilly was Chief Executive Officer of PhotoThera, Inc., a medical device company, from January 2012 to December 2012. Since 2010 Dr. Dilly has served as an independent director of Sangamo Biosciences, Inc., a biopharmaceutical company, where he also currently serves as chair of the clinical review committee. From 2006 to 2011 Dr. Dilly served as President and Chief Executive Officer and a member of the board of directors of APT Pharmaceuticals, Inc., a drug development company. From 2007 to 2009 he was a member of the board of directors of Avigen, Inc., a biopharmaceutical company, which merged with MediciNova, Inc. in December 2009. From 2003 to 2006 he served as Chief Medical Officer and Senior Vice President of Development of Chiron BioPharma, a biotechnology company which was later acquired by Novartis International AG. From 1998 to 2003 Dr. Dilly held various management positions at Genentech, Inc. “Genentech”, a biotechnology company, including Vice President of Development Sciences from 2002 to 2003 and Vice President of Medical Affairs from 1998 to 2001. From 1988 to 1998 Dr. Dilly held various management positions in drug development with SmithKline Beecham, PLC, a healthcare company in the U.K. During his career, Dr. Dilly has been closely associated with the development and launch of marketed drugs for many therapeutic areas, including Kytril, Paxil, Kredex, Requip, TNKase, Xolair, Avastin, Raptiva, Tarceva, Lucentis and Cubicin. Dr. Dilly received an M.B.B.S., the equivalent of an M.D., from the University of London in the U.K. and a Ph.D. in cardiac physiology from University of London. - Stephen G. Dilly，2010年3月起担任公司董事会成员。2012年1月孩子12月，他担任医疗设备公司PhotoThera, Inc.的首席执行官。2006至2011年12月，他担任药物研发公司APT Pharmaceuticals, Inc.的总裁、首席执行官、董事会成员。2007至2009年，他担任生物制药公司Avigen, Inc.的董事会成员，该公司2009年12月与MediciNova, Inc.合并。2003至2006年，他担任生物科技公司Chiron BioPharma的首席医务官和发展部高级副总裁，该公司后被Novartis International AG收购。1998至2003年，他在Genentech, Inc.担任多个职位，包括2002至2003年任发展科学副总裁，1998至2001担任医疗事务副总裁。1988至1998年，他在英国SmithKline Beecham担任药物开发多个管理职位。在此期间，他密切协助诸多治疗领域的市场化药品的开发和推广，包括Kytril, Paxil, Kredex, Requip, TNKase, Xolair, Avastin, Raptiva, Tarceva, Lucentis以及Cubicin。他现任Allergen Research Corporation Inc.的执行主席。1982年，他获得英国University of London的硕士学位，1988年获得University of London心脏生理学博士学位。
- Stephen G. Dilly, M.B.B.S., Ph.D. has served as our Chief Executive Officer since April 2014 and as a member of our Board since April 2013. Dr. Dilly was Chief Executive Officer of PhotoThera, Inc., a medical device company, from January 2012 to December 2012. Since 2010 Dr. Dilly has served as an independent director of Sangamo Biosciences, Inc., a biopharmaceutical company, where he also currently serves as chair of the clinical review committee. From 2006 to 2011 Dr. Dilly served as President and Chief Executive Officer and a member of the board of directors of APT Pharmaceuticals, Inc., a drug development company. From 2007 to 2009 he was a member of the board of directors of Avigen, Inc., a biopharmaceutical company, which merged with MediciNova, Inc. in December 2009. From 2003 to 2006 he served as Chief Medical Officer and Senior Vice President of Development of Chiron BioPharma, a biotechnology company which was later acquired by Novartis International AG. From 1998 to 2003 Dr. Dilly held various management positions at Genentech, Inc. “Genentech”, a biotechnology company, including Vice President of Development Sciences from 2002 to 2003 and Vice President of Medical Affairs from 1998 to 2001. From 1988 to 1998 Dr. Dilly held various management positions in drug development with SmithKline Beecham, PLC, a healthcare company in the U.K. During his career, Dr. Dilly has been closely associated with the development and launch of marketed drugs for many therapeutic areas, including Kytril, Paxil, Kredex, Requip, TNKase, Xolair, Avastin, Raptiva, Tarceva, Lucentis and Cubicin. Dr. Dilly received an M.B.B.S., the equivalent of an M.D., from the University of London in the U.K. and a Ph.D. in cardiac physiology from University of London.
- Mark D. McDade
-
Mark D. McDade，自2006年7月，一直担任我们的董事。他目前担任UCB S.A创立品牌，解决方案和供应的执行副总裁，他在2008年4月加入该公司。UCB是一家全球性生物制药公司专注于创新药物的发现和开发。他曾担任 PDL BioPharma首席执行官董事，这是一家生物技术公司；并任Signature BioScience的首席执行官，这是一家药物研发公司，致力于开发治疗和线索在癌症和其他疾病。他还担任Corixa公司董事和 高级职员，这是他共同创立的公司专注于开发调节免疫功能的创新产品。在Corixa，他最近担任其总裁兼首席运营官。他获得了Dartmouth学院学士学位和哈佛商学院工商管理硕士学位。
Mark D. McDade has served as a member of our board of directors since November 2018. Since January 2017 Mr. McDade has been Managing Partner of the Qiming US Healthcare Fund, a venture capital firm based in Seattle and formed in January 2017. Prior to Qiming, from April 2008 Mr. McDade was Executive Vice President, Corporate Development, and from January 2009 EVP and Chief Operating Officer, at UCB S.A. OTC: UCBJF, a Belgian biopharmaceutical company, until his retirement from UCB in October 2016. From November 2002 to September 2007 Mr. McDade served as Chief Executive Officer and a member of the board of directors of PDL BioPharma, Inc. (Nasdaq: PDLI), a biotechnology company. From 2000 to 2002 Mr. McDade was Chief Executive Officer of Signature BioScience, Inc., a drug discovery company. Mr. McDade currently serves on the board of directors of Lupin Limited, a global biopharmaceutical company based in Mumbai, India. Previously, Mr. McDade also served on the board of directors of Dermira, Inc. (Nasdaq: DERM), and as chairman of the board of Aimmune Therapeutics, Inc. (Nasdaq: AIMT), until both companies were acquired by Eli Lilly and Company (NYSE: LLY) and Nestle SA (OTC: NSRGY), respectively, in March and October 2020. Previously, Mr. McDade also served on the board of directors of publicly traded companies Phillips Edison Grocery Center REIT II, Inc. and Five Prime Therapeutics, Inc. (Nasdaq: FPRX). Mr. McDade received a BA in History from Dartmouth College and an MBA from the Harvard Business School. - Mark D. McDade，自2006年7月，一直担任我们的董事。他目前担任UCB S.A创立品牌，解决方案和供应的执行副总裁，他在2008年4月加入该公司。UCB是一家全球性生物制药公司专注于创新药物的发现和开发。他曾担任 PDL BioPharma首席执行官董事，这是一家生物技术公司；并任Signature BioScience的首席执行官，这是一家药物研发公司，致力于开发治疗和线索在癌症和其他疾病。他还担任Corixa公司董事和 高级职员，这是他共同创立的公司专注于开发调节免疫功能的创新产品。在Corixa，他最近担任其总裁兼首席运营官。他获得了Dartmouth学院学士学位和哈佛商学院工商管理硕士学位。
- Mark D. McDade has served as a member of our board of directors since November 2018. Since January 2017 Mr. McDade has been Managing Partner of the Qiming US Healthcare Fund, a venture capital firm based in Seattle and formed in January 2017. Prior to Qiming, from April 2008 Mr. McDade was Executive Vice President, Corporate Development, and from January 2009 EVP and Chief Operating Officer, at UCB S.A. OTC: UCBJF, a Belgian biopharmaceutical company, until his retirement from UCB in October 2016. From November 2002 to September 2007 Mr. McDade served as Chief Executive Officer and a member of the board of directors of PDL BioPharma, Inc. (Nasdaq: PDLI), a biotechnology company. From 2000 to 2002 Mr. McDade was Chief Executive Officer of Signature BioScience, Inc., a drug discovery company. Mr. McDade currently serves on the board of directors of Lupin Limited, a global biopharmaceutical company based in Mumbai, India. Previously, Mr. McDade also served on the board of directors of Dermira, Inc. (Nasdaq: DERM), and as chairman of the board of Aimmune Therapeutics, Inc. (Nasdaq: AIMT), until both companies were acquired by Eli Lilly and Company (NYSE: LLY) and Nestle SA (OTC: NSRGY), respectively, in March and October 2020. Previously, Mr. McDade also served on the board of directors of publicly traded companies Phillips Edison Grocery Center REIT II, Inc. and Five Prime Therapeutics, Inc. (Nasdaq: FPRX). Mr. McDade received a BA in History from Dartmouth College and an MBA from the Harvard Business School.
高管简历
中英对照 | 中文 | 英文- Warren L. DeSouza
Warren L. DeSouza，2015年4月以来，他一直担任我们的首席财务官。他曾担任Onyx Pharmaceuticals公司（Onyx，生物制药公司）的财务事务顾问（从2013年8月到2014年1月），期间公司被Amgen公司收购。从2005年1月到2013年8月，他曾担任Onyx公司的财务副总裁，在那里他曾领导会计、SEC报告、采购、税收、财政和风险管理。从2002年到2005年，他曾担任Deloitte & Touche公司（会计公司）的高级经理。从1990年到2002年，他曾担任Arthur Andersen公司（会计公司）的高级经理。他持有the University of Notre Dame的工商管理学士学位，也是注册会计师（不活跃）。
Warren L. DeSouza has served as our Chief Financial Officer since April 2015. Mr. DeSouza served as a consultant on financial matters to Onyx Pharmaceuticals, Inc., or Onyx, a biopharmaceutical company, from August 2013 to January 2014 during which the company was acquired by Amgen, Inc. From January 2005 to August 2013 Mr. DeSouza served as Vice President, Finance for Onyx, where he led accounting, SEC reporting, purchasing, tax, treasury and risk management. From 2002 to 2005 Mr. DeSouza served as a senior manager at Deloitte & Touche LLP, an accounting firm. From 1990 to 2002 Mr. DeSouza was a senior manager at Arthur Andersen LLP, an accounting firm. Mr. DeSouza received a Bachelor of Arts in Business Administration from the University of Notre Dame and is a certified public accountant inactive. On February 3 2017 we entered into a Transition and Separation Agreement (the “Transition and Separation Agreement”) with Mr. DeSouza, whereby he will continue to be employed by the Company until April 16 2017.- Warren L. DeSouza，2015年4月以来，他一直担任我们的首席财务官。他曾担任Onyx Pharmaceuticals公司（Onyx，生物制药公司）的财务事务顾问（从2013年8月到2014年1月），期间公司被Amgen公司收购。从2005年1月到2013年8月，他曾担任Onyx公司的财务副总裁，在那里他曾领导会计、SEC报告、采购、税收、财政和风险管理。从2002年到2005年，他曾担任Deloitte & Touche公司（会计公司）的高级经理。从1990年到2002年，他曾担任Arthur Andersen公司（会计公司）的高级经理。他持有the University of Notre Dame的工商管理学士学位，也是注册会计师（不活跃）。
- Warren L. DeSouza has served as our Chief Financial Officer since April 2015. Mr. DeSouza served as a consultant on financial matters to Onyx Pharmaceuticals, Inc., or Onyx, a biopharmaceutical company, from August 2013 to January 2014 during which the company was acquired by Amgen, Inc. From January 2005 to August 2013 Mr. DeSouza served as Vice President, Finance for Onyx, where he led accounting, SEC reporting, purchasing, tax, treasury and risk management. From 2002 to 2005 Mr. DeSouza served as a senior manager at Deloitte & Touche LLP, an accounting firm. From 1990 to 2002 Mr. DeSouza was a senior manager at Arthur Andersen LLP, an accounting firm. Mr. DeSouza received a Bachelor of Arts in Business Administration from the University of Notre Dame and is a certified public accountant inactive. On February 3 2017 we entered into a Transition and Separation Agreement (the “Transition and Separation Agreement”) with Mr. DeSouza, whereby he will continue to be employed by the Company until April 16 2017.
- Mary M. Rozenman
Mary M. Rozenman，她担任我们的高级副总裁，负责企业和商业开发（2015年2月以来）。从2013年2月到2015年1月，她曾担任Longitude Capital Management公司（一个风险投资公司）的副总裁，在那里她专注于治疗、诊断和研究和开发工具和服务的生物技术投资。从2008年2月到2013年1月，她曾任职McKinsey & Company（管理咨询公司），在那里她最近担任副负责人。她此前曾担任Esperion Therapeutics公司（一家生物制药公司）、CardioDx公司（一个分子诊断公司）的董事会监察员。她持有Columbia University的生物化学学士学位和俄罗斯文学学士学位，以及Harvard University的有机化学和化学生物学博士学位。
Mary M. Rozenman, Ph.D. has served as our Senior Vice President, Strategy & Corporate Development since February 2016. From February 2015 to February 2016 Dr. Rozenman served as our Senior Vice President, Corporate and Commercial Development. From February 2013 to January 2015 Dr. Rozenman was Vice President at Longitude Capital Management Co., LLC, a venture investment company, where she focused on biotechnology investments in therapeutics and diagnostics. From February 2008 to January 2013 Dr. Rozenman was at McKinsey & Company, a management-consulting company, where she most recently served as Associate Principal in the Healthcare and Corporate Finance practices. Dr. Rozenman previously served as an observer on the boards of directors of Allergen Research Corporation now Aimmune Therapeutics, Inc., Esperion Therapeutics, Inc., a biopharmaceutical company, and CardioDx, Inc., a molecular diagnostics company. Dr. Rozenman received a B.A. in Biochemistry and Russian Literature from Columbia University and a Ph.D. in Organic Chemistry and Chemical Biology from Harvard University.- Mary M. Rozenman，她担任我们的高级副总裁，负责企业和商业开发（2015年2月以来）。从2013年2月到2015年1月，她曾担任Longitude Capital Management公司（一个风险投资公司）的副总裁，在那里她专注于治疗、诊断和研究和开发工具和服务的生物技术投资。从2008年2月到2013年1月，她曾任职McKinsey & Company（管理咨询公司），在那里她最近担任副负责人。她此前曾担任Esperion Therapeutics公司（一家生物制药公司）、CardioDx公司（一个分子诊断公司）的董事会监察员。她持有Columbia University的生物化学学士学位和俄罗斯文学学士学位，以及Harvard University的有机化学和化学生物学博士学位。
- Mary M. Rozenman, Ph.D. has served as our Senior Vice President, Strategy & Corporate Development since February 2016. From February 2015 to February 2016 Dr. Rozenman served as our Senior Vice President, Corporate and Commercial Development. From February 2013 to January 2015 Dr. Rozenman was Vice President at Longitude Capital Management Co., LLC, a venture investment company, where she focused on biotechnology investments in therapeutics and diagnostics. From February 2008 to January 2013 Dr. Rozenman was at McKinsey & Company, a management-consulting company, where she most recently served as Associate Principal in the Healthcare and Corporate Finance practices. Dr. Rozenman previously served as an observer on the boards of directors of Allergen Research Corporation now Aimmune Therapeutics, Inc., Esperion Therapeutics, Inc., a biopharmaceutical company, and CardioDx, Inc., a molecular diagnostics company. Dr. Rozenman received a B.A. in Biochemistry and Russian Literature from Columbia University and a Ph.D. in Organic Chemistry and Chemical Biology from Harvard University.
- Susan E. Barrowcliffe
Susan E. Barrowcliffe，2016年1月以来，她担任我们高级副总裁和欧洲总经理。从2015年5月到2015年1月，她担任我们高级副总裁、全球监管事务负责人和欧洲总经理。从2007年1月到2015年5月，她曾是Right Track Regulatory Ltd（生物技术公司的咨询公司）的独立董事和顾问。从2013年4月到2015年5月，她曾是Idis（医药公司，Clinigen Group的一部分）的非执行董事。从2004年10月到2006年12月，她曾是Chiron BioPharmaceuticals（一个制药公司）的欧洲法规事务副总裁。从1990年1月至2003年12月，她担任British Biotech发展副总裁、SmithKline Beecham的全球产品注册副总裁和Marion Merrell Dow的欧洲法规事务主管。她获得英国the University of Sheffield的生物化学一级荣誉学位。
Susan E. Barrowcliffe has served as our Senior Vice President, General Manager of Europe since January 2016. From May 2015 to January 2015 she served as our Senior Vice President, Head of Worldwide Regulatory Affairs and General Manager Europe. From 2007 to May 2015 Ms. Barrowcliffe was sole director and consultant of Right Track Regulatory Ltd, a consultancy firm for biotech companies. From April 2013 to May 2015 she was a non-executive board director for Idis, a pharmaceutical company now a part of Clinigen Group. From 2004 to 2006 Ms. Barrowcliffe was VP of Regulatory Affairs Europe for Chiron BioPharmaceuticals, a pharmaceutical company. From 1990 to 2003 she served as VP Development for British Biotech, VP of Worldwide Product Registration for SmithKline Beecham, and Director of European Regulatory Affairs for Marion Merrell Dow. Ms. Barrowcliffe has a first class honours degree in Biochemistry from the University of Sheffield, United Kingdom.- Susan E. Barrowcliffe，2016年1月以来，她担任我们高级副总裁和欧洲总经理。从2015年5月到2015年1月，她担任我们高级副总裁、全球监管事务负责人和欧洲总经理。从2007年1月到2015年5月，她曾是Right Track Regulatory Ltd（生物技术公司的咨询公司）的独立董事和顾问。从2013年4月到2015年5月，她曾是Idis（医药公司，Clinigen Group的一部分）的非执行董事。从2004年10月到2006年12月，她曾是Chiron BioPharmaceuticals（一个制药公司）的欧洲法规事务副总裁。从1990年1月至2003年12月，她担任British Biotech发展副总裁、SmithKline Beecham的全球产品注册副总裁和Marion Merrell Dow的欧洲法规事务主管。她获得英国the University of Sheffield的生物化学一级荣誉学位。
- Susan E. Barrowcliffe has served as our Senior Vice President, General Manager of Europe since January 2016. From May 2015 to January 2015 she served as our Senior Vice President, Head of Worldwide Regulatory Affairs and General Manager Europe. From 2007 to May 2015 Ms. Barrowcliffe was sole director and consultant of Right Track Regulatory Ltd, a consultancy firm for biotech companies. From April 2013 to May 2015 she was a non-executive board director for Idis, a pharmaceutical company now a part of Clinigen Group. From 2004 to 2006 Ms. Barrowcliffe was VP of Regulatory Affairs Europe for Chiron BioPharmaceuticals, a pharmaceutical company. From 1990 to 2003 she served as VP Development for British Biotech, VP of Worldwide Product Registration for SmithKline Beecham, and Director of European Regulatory Affairs for Marion Merrell Dow. Ms. Barrowcliffe has a first class honours degree in Biochemistry from the University of Sheffield, United Kingdom.
- Daniel C. Adelman
DanielC.Adelman自2016年6月起担任我们的首席医疗官。从2009年到2015年9月，Adelman博士担任生物制药公司Alvine Pharmaceuticals，Inc.的首席医疗官兼发展高级副总裁。此外，Adelman博士于2011年至2016年6月担任非营利组织Food Allergy Research&Education Fare，Inc.的研究咨询委员会成员。从2003年到2008年，Adelman博士担任SunesisPharmaceuticals，Inc.公司（一家制药公司）的首席医疗官和发展高级副总裁。从1998年到2003年，Adelman博士在Pharmacyclics，Inc.担任过多个职位，这是一家制药公司，包括临床操作和生物识别技术的Vice President。从1994年到1998年，Adelman博士担任Genentech的临床科学家。Adelman博士目前也是加州大学旧金山分校（University of California，San Francisco）的医学兼职教授，在那里他教授和实践超过25年。Adelman博士在加州大学伯克利分校（University of California，Berkeley）获得生物学A.B.学位，在加州大学戴维斯分校（University of California，Davis）获得医学博士学位。
Daniel C. Adelman has served as our Chief Medical Officer since June 2016. From 2009 to September 2015 Dr. Adelman served as Chief Medical Officer and Senior Vice President of Development of Alvine Pharmaceuticals, Inc., a biopharmaceutical company. Additionally, Dr. Adelman was a member of the Research Advisory Board of Food Allergy Research & Education FARE, Inc., a nonprofit organization, from 2011 to June 2016. From 2003 to 2008 Dr. Adelman as Chief Medical Officer and Senior Vice President of Development at Sunesis Pharmaceuticals, Inc., a pharmaceutical company. From 1998 to 2003 Dr. Adelman held various positions at Pharmacyclics, Inc., a pharmaceutical company, including Vice President of Clinical Operations and Biometrics. From 1994 to 1998 Dr. Adelman served as Clinical Scientist at Genentech. Dr. Adelman is also currently an Adjunct Professor of Medicine at the University of California, San Francisco, where he has taught and practiced for more than 25 years. Dr. Adelman received an A.B. degree in Biology from the University of California, Berkeley, and an M.D. from the University of California, Davis.- DanielC.Adelman自2016年6月起担任我们的首席医疗官。从2009年到2015年9月，Adelman博士担任生物制药公司Alvine Pharmaceuticals，Inc.的首席医疗官兼发展高级副总裁。此外，Adelman博士于2011年至2016年6月担任非营利组织Food Allergy Research&Education Fare，Inc.的研究咨询委员会成员。从2003年到2008年，Adelman博士担任SunesisPharmaceuticals，Inc.公司（一家制药公司）的首席医疗官和发展高级副总裁。从1998年到2003年，Adelman博士在Pharmacyclics，Inc.担任过多个职位，这是一家制药公司，包括临床操作和生物识别技术的Vice President。从1994年到1998年，Adelman博士担任Genentech的临床科学家。Adelman博士目前也是加州大学旧金山分校（University of California，San Francisco）的医学兼职教授，在那里他教授和实践超过25年。Adelman博士在加州大学伯克利分校（University of California，Berkeley）获得生物学A.B.学位，在加州大学戴维斯分校（University of California，Davis）获得医学博士学位。
- Daniel C. Adelman has served as our Chief Medical Officer since June 2016. From 2009 to September 2015 Dr. Adelman served as Chief Medical Officer and Senior Vice President of Development of Alvine Pharmaceuticals, Inc., a biopharmaceutical company. Additionally, Dr. Adelman was a member of the Research Advisory Board of Food Allergy Research & Education FARE, Inc., a nonprofit organization, from 2011 to June 2016. From 2003 to 2008 Dr. Adelman as Chief Medical Officer and Senior Vice President of Development at Sunesis Pharmaceuticals, Inc., a pharmaceutical company. From 1998 to 2003 Dr. Adelman held various positions at Pharmacyclics, Inc., a pharmaceutical company, including Vice President of Clinical Operations and Biometrics. From 1994 to 1998 Dr. Adelman served as Clinical Scientist at Genentech. Dr. Adelman is also currently an Adjunct Professor of Medicine at the University of California, San Francisco, where he has taught and practiced for more than 25 years. Dr. Adelman received an A.B. degree in Biology from the University of California, Berkeley, and an M.D. from the University of California, Davis.
- Jeffrey H. Knapp
Jeffrey H. Knapp，2006年7月以来，他一直担任我们的首席商业官。从2005年11月到2006年4月，他曾担任Abgenix公司（生物制药公司）的负责销售和营销的高级副总裁。从2004年10月到2005年7月，他曾担任Pharmion Corporation（制药公司）的销售和营销副总裁。从2001年11月到2004年10月，他曾担任EMD Pharmaceuticals公司（Merck KGaA公司的子公司，制药公司）的副总裁，负责美国销售和营销。他也曾担任Eli Lilly and Company、Schering-Plough Corporation（制药公司）的销售、营销和商业开发职务。他持有Wittenberg University的学士学位。
Jeffrey H. Knapp has served as our Chief Operating Officer since February 2016. Mr. Knapp previously served as Chief Operating Officer of Adamas Pharmaceuticals, Inc., a pharmaceutical company, from August 2014 to January 2016. Prior to serving as Chief Operating Officer of Adamas, Mr. Knapp served as its Chief Commercial Officer from February 2014 to August 2014. From 2006 to March 2013 Mr. Knapp served as Chief Commercial Officer at Affymax Inc., a pharmaceutical company. Mr. Knapp served as Senior Vice President, Sales and Marketing at Abgenix, Inc., a pharmaceutical company, from 2005 to 2006. Prior to 2005 Mr. Knapp served in a variety of commercial leadership positions within the pharmaceutical industry, including with Schering-Plough Corporation now Merck & Co. Inc. and Eli Lilly & Company. Mr. Knapp received a B.A. in Biology from Wittenberg University.- Jeffrey H. Knapp，2006年7月以来，他一直担任我们的首席商业官。从2005年11月到2006年4月，他曾担任Abgenix公司（生物制药公司）的负责销售和营销的高级副总裁。从2004年10月到2005年7月，他曾担任Pharmion Corporation（制药公司）的销售和营销副总裁。从2001年11月到2004年10月，他曾担任EMD Pharmaceuticals公司（Merck KGaA公司的子公司，制药公司）的副总裁，负责美国销售和营销。他也曾担任Eli Lilly and Company、Schering-Plough Corporation（制药公司）的销售、营销和商业开发职务。他持有Wittenberg University的学士学位。
- Jeffrey H. Knapp has served as our Chief Operating Officer since February 2016. Mr. Knapp previously served as Chief Operating Officer of Adamas Pharmaceuticals, Inc., a pharmaceutical company, from August 2014 to January 2016. Prior to serving as Chief Operating Officer of Adamas, Mr. Knapp served as its Chief Commercial Officer from February 2014 to August 2014. From 2006 to March 2013 Mr. Knapp served as Chief Commercial Officer at Affymax Inc., a pharmaceutical company. Mr. Knapp served as Senior Vice President, Sales and Marketing at Abgenix, Inc., a pharmaceutical company, from 2005 to 2006. Prior to 2005 Mr. Knapp served in a variety of commercial leadership positions within the pharmaceutical industry, including with Schering-Plough Corporation now Merck & Co. Inc. and Eli Lilly & Company. Mr. Knapp received a B.A. in Biology from Wittenberg University.
- Stephen G. Dilly
Stephen G. Dilly，2010年3月起担任公司董事会成员。2012年1月孩子12月，他担任医疗设备公司PhotoThera, Inc.的首席执行官。2006至2011年12月，他担任药物研发公司APT Pharmaceuticals, Inc.的总裁、首席执行官、董事会成员。2007至2009年，他担任生物制药公司Avigen, Inc.的董事会成员，该公司2009年12月与MediciNova, Inc.合并。2003至2006年，他担任生物科技公司Chiron BioPharma的首席医务官和发展部高级副总裁，该公司后被Novartis International AG收购。1998至2003年，他在Genentech, Inc.担任多个职位，包括2002至2003年任发展科学副总裁，1998至2001担任医疗事务副总裁。1988至1998年，他在英国SmithKline Beecham担任药物开发多个管理职位。在此期间，他密切协助诸多治疗领域的市场化药品的开发和推广，包括Kytril, Paxil, Kredex, Requip, TNKase, Xolair, Avastin, Raptiva, Tarceva, Lucentis以及Cubicin。他现任Allergen Research Corporation Inc.的执行主席。1982年，他获得英国University of London的硕士学位，1988年获得University of London心脏生理学博士学位。
Stephen G. Dilly, M.B.B.S., Ph.D. has served as our Chief Executive Officer since April 2014 and as a member of our Board since April 2013. Dr. Dilly was Chief Executive Officer of PhotoThera, Inc., a medical device company, from January 2012 to December 2012. Since 2010 Dr. Dilly has served as an independent director of Sangamo Biosciences, Inc., a biopharmaceutical company, where he also currently serves as chair of the clinical review committee. From 2006 to 2011 Dr. Dilly served as President and Chief Executive Officer and a member of the board of directors of APT Pharmaceuticals, Inc., a drug development company. From 2007 to 2009 he was a member of the board of directors of Avigen, Inc., a biopharmaceutical company, which merged with MediciNova, Inc. in December 2009. From 2003 to 2006 he served as Chief Medical Officer and Senior Vice President of Development of Chiron BioPharma, a biotechnology company which was later acquired by Novartis International AG. From 1998 to 2003 Dr. Dilly held various management positions at Genentech, Inc. “Genentech”, a biotechnology company, including Vice President of Development Sciences from 2002 to 2003 and Vice President of Medical Affairs from 1998 to 2001. From 1988 to 1998 Dr. Dilly held various management positions in drug development with SmithKline Beecham, PLC, a healthcare company in the U.K. During his career, Dr. Dilly has been closely associated with the development and launch of marketed drugs for many therapeutic areas, including Kytril, Paxil, Kredex, Requip, TNKase, Xolair, Avastin, Raptiva, Tarceva, Lucentis and Cubicin. Dr. Dilly received an M.B.B.S., the equivalent of an M.D., from the University of London in the U.K. and a Ph.D. in cardiac physiology from University of London.- Stephen G. Dilly，2010年3月起担任公司董事会成员。2012年1月孩子12月，他担任医疗设备公司PhotoThera, Inc.的首席执行官。2006至2011年12月，他担任药物研发公司APT Pharmaceuticals, Inc.的总裁、首席执行官、董事会成员。2007至2009年，他担任生物制药公司Avigen, Inc.的董事会成员，该公司2009年12月与MediciNova, Inc.合并。2003至2006年，他担任生物科技公司Chiron BioPharma的首席医务官和发展部高级副总裁，该公司后被Novartis International AG收购。1998至2003年，他在Genentech, Inc.担任多个职位，包括2002至2003年任发展科学副总裁，1998至2001担任医疗事务副总裁。1988至1998年，他在英国SmithKline Beecham担任药物开发多个管理职位。在此期间，他密切协助诸多治疗领域的市场化药品的开发和推广，包括Kytril, Paxil, Kredex, Requip, TNKase, Xolair, Avastin, Raptiva, Tarceva, Lucentis以及Cubicin。他现任Allergen Research Corporation Inc.的执行主席。1982年，他获得英国University of London的硕士学位，1988年获得University of London心脏生理学博士学位。
- Stephen G. Dilly, M.B.B.S., Ph.D. has served as our Chief Executive Officer since April 2014 and as a member of our Board since April 2013. Dr. Dilly was Chief Executive Officer of PhotoThera, Inc., a medical device company, from January 2012 to December 2012. Since 2010 Dr. Dilly has served as an independent director of Sangamo Biosciences, Inc., a biopharmaceutical company, where he also currently serves as chair of the clinical review committee. From 2006 to 2011 Dr. Dilly served as President and Chief Executive Officer and a member of the board of directors of APT Pharmaceuticals, Inc., a drug development company. From 2007 to 2009 he was a member of the board of directors of Avigen, Inc., a biopharmaceutical company, which merged with MediciNova, Inc. in December 2009. From 2003 to 2006 he served as Chief Medical Officer and Senior Vice President of Development of Chiron BioPharma, a biotechnology company which was later acquired by Novartis International AG. From 1998 to 2003 Dr. Dilly held various management positions at Genentech, Inc. “Genentech”, a biotechnology company, including Vice President of Development Sciences from 2002 to 2003 and Vice President of Medical Affairs from 1998 to 2001. From 1988 to 1998 Dr. Dilly held various management positions in drug development with SmithKline Beecham, PLC, a healthcare company in the U.K. During his career, Dr. Dilly has been closely associated with the development and launch of marketed drugs for many therapeutic areas, including Kytril, Paxil, Kredex, Requip, TNKase, Xolair, Avastin, Raptiva, Tarceva, Lucentis and Cubicin. Dr. Dilly received an M.B.B.S., the equivalent of an M.D., from the University of London in the U.K. and a Ph.D. in cardiac physiology from University of London.
- Douglas T. Sheehy
Douglas T. Sheehy，2014年2月，担任Codexis的执行副总裁、 首席行政官、总顾问和秘书。2009年11月至2014年2月，他担任Codexis 的高级副总裁、总顾问、秘书。2007年4月，Sheehy先生加入Codexis公司，并担任副总裁、总顾问和秘书。加入 Codexis之前， 他在 CV Therapeutics公司工作了5年。这是一家研发和销售治疗心血管疾病的小分子药物的生物制药上市公司。他在该公司担任过多种职务。最近，他担任公司的企业法执行董事。在那以前， Sheehy先生是 Gunderson Dettmer LLP和Brobeck Phleger & Harrison LLP这两家律师事务所的律师。他在达特茅斯学院获得了历史学学士，在美利坚大学获得了法学博士学位。
Douglas T. Sheehy has served as our General Counsel and Secretary since April 2016. Prior to joining Aimmune, Mr. Sheehy served as Executive Vice President, Chief Administrative Officer, General Counsel and Secretary of Codexis, Inc., a developer of biocatalysts for the pharmaceutical and fine chemical industries, from February 2014 to April 2016 as Senior Vice President, General Counsel and Secretary from 2009 to February 2014 and as Vice President, General Counsel and Secretary from 2007 to 2009. Prior to Codexis, Mr. Sheehy spent five years in key legal roles at CV Therapeutics, Inc., a publicly-held biopharmaceutical company that was subsequently acquired by Gilead Sciences, Inc. in 2009. He began his legal career as a corporate attorney at Gunderson Dettmer LLP. Mr. Sheehy holds a B.A. in history from Dartmouth College and a J.D. from American University, where he was Editor-in-Chief of the American University Law Review.- Douglas T. Sheehy，2014年2月，担任Codexis的执行副总裁、 首席行政官、总顾问和秘书。2009年11月至2014年2月，他担任Codexis 的高级副总裁、总顾问、秘书。2007年4月，Sheehy先生加入Codexis公司，并担任副总裁、总顾问和秘书。加入 Codexis之前， 他在 CV Therapeutics公司工作了5年。这是一家研发和销售治疗心血管疾病的小分子药物的生物制药上市公司。他在该公司担任过多种职务。最近，他担任公司的企业法执行董事。在那以前， Sheehy先生是 Gunderson Dettmer LLP和Brobeck Phleger & Harrison LLP这两家律师事务所的律师。他在达特茅斯学院获得了历史学学士，在美利坚大学获得了法学博士学位。
- Douglas T. Sheehy has served as our General Counsel and Secretary since April 2016. Prior to joining Aimmune, Mr. Sheehy served as Executive Vice President, Chief Administrative Officer, General Counsel and Secretary of Codexis, Inc., a developer of biocatalysts for the pharmaceutical and fine chemical industries, from February 2014 to April 2016 as Senior Vice President, General Counsel and Secretary from 2009 to February 2014 and as Vice President, General Counsel and Secretary from 2007 to 2009. Prior to Codexis, Mr. Sheehy spent five years in key legal roles at CV Therapeutics, Inc., a publicly-held biopharmaceutical company that was subsequently acquired by Gilead Sciences, Inc. in 2009. He began his legal career as a corporate attorney at Gunderson Dettmer LLP. Mr. Sheehy holds a B.A. in history from Dartmouth College and a J.D. from American University, where he was Editor-in-Chief of the American University Law Review.